LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Elenco Azioni・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

1.91 1.06

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.87

Massimo

1.9100000000000001

Metriche Chiave
By Trading Economics
Entrata	14M -1M
Vendite	16M 21M
EPS	-0.003
Margine di Profitto	-4.943
Dipendenti	81
EBITDA	14M -996K

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+163.35% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	209M 919M
Apertura precedente	0.85
Chiusura precedente	1.91

Notizie sul Sentiment di mercato

By Acuity

28%

72%

60 / 344 Classifica in Healthcare

Lexicon Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 giu 2026, 19:20 UTC

I principali Market Mover

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

6 giu 2026, 08:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

6 giu 2026, 08:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

6 giu 2026, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

6 giu 2026, 00:14 UTC

Acquisizioni, Fusioni, Takeovers

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 giu 2026, 21:27 UTC

Utili

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 giu 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

5 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

5 giu 2026, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 giu 2026, 20:19 UTC

Acquisizioni, Fusioni, Takeovers

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 giu 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

5 giu 2026, 19:26 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 giu 2026, 19:26 UTC

Discorsi di Mercato

Hog Futures Tumble to Close Week -- Market Talk

5 giu 2026, 19:10 UTC

Discorsi di Mercato

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 giu 2026, 19:03 UTC

Discorsi di Mercato

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 giu 2026, 18:59 UTC

Discorsi di Mercato

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 giu 2026, 18:47 UTC

Discorsi di Mercato

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 giu 2026, 18:34 UTC

Discorsi di Mercato

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 giu 2026, 18:33 UTC

Acquisizioni, Fusioni, Takeovers

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 giu 2026, 17:50 UTC

Utili

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 giu 2026, 17:27 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 giu 2026, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

5 giu 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

5 giu 2026, 15:44 UTC

Acquisizioni, Fusioni, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 giu 2026, 15:26 UTC

Discorsi di Mercato

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 giu 2026, 15:25 UTC

Utili

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 giu 2026, 15:16 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Lexicon Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

163.35% in crescita

Previsioni per 12 mesi

Media 5.03 USD 163.35%

Alto 6 USD

Basso 3.1 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lexicon Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 3 che hanno fornito valutazioni azionarie a Lexicon Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

60 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.